Ra223

Phase 3Small molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Ra223 is one of 38 small molecule programs targeting Metastatic Hormone-Sensitive Prostate Cance. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Hormone-Sensitive Prostate CanceNot yet recruiting

Phase IIActive, not recruiting

Metastatic Hormone-Sensitive Prostate CancePhase 2

Not yet recruiting

Phase IIPhase 3

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Phase II

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Rituxan

Roche

Phase 2

4 3

Lynparza

AstraZeneca

Phase 2

2 4

Eloxatin

Teva

Phase 2

2 5

Polivy

Roche

Phase 2

1 6

Imfinzi

AstraZeneca

Phase 2

1 7

Avastin

Roche

Phase 2

1 8

Adriamycin

Pfizer

Phase 2

1 9

Calquence

AstraZeneca

Phase 2

1 10

LUNSUMIO

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Phase II

NCT02194842

Q4 2029

Phase 2Not yet recruiting

Metastatic Hormone-Sensitive Prostate Cance

NCT07717099

Clinical

Trials by Indication[1]

Phase II1 trial

Phase III Radium 223 mCRPC-PEACE III

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT02194842·446 enrolled

Metastatic Hormone-Sensitive Prostate Cance1 trial

Quantitative Unified Assessment of Novel Triplet Therapy and Unconventional Maintenance With Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

Not yet recruiting·AAlianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD·Phase 2·NCT07717099·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ra223. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ra223 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ra223. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

Ra223

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2029

Trials by Indication[1]

Phase II1 trial

Metastatic Hormone-Sensitive Prostate Cance1 trial

References

Drug Info

Quick Facts

Related News